Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OS Therapies Inc OSTX

Healthcare Biotechnology
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the... see more

Recent & Breaking News (NYSEAM:OSTX)

OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma

Business Wire 8 days ago

OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire January 2, 2025

OS Therapies Announces Closing of $6 Million Private Placement

Business Wire December 31, 2024

OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online

Business Wire December 26, 2024

OS Therapies Announces Pricing of $6 Million Private Placement

Business Wire December 24, 2024

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire November 15, 2024

OS Therapies to Present at The Spartan Capital Investor Conference

Business Wire November 4, 2024

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

Business Wire October 30, 2024

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Business Wire October 28, 2024

OS Therapies to Present at the LD Micro Main Event XVII

Business Wire October 24, 2024

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Business Wire October 17, 2024

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Business Wire October 3, 2024

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

Business Wire September 13, 2024

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Accesswire September 11, 2024

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

Business Wire September 5, 2024

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

Business Wire August 29, 2024

OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

Business Wire August 22, 2024

OS Therapies Clarifies CUSIP of Common Stock

Business Wire August 22, 2024

OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

Business Wire August 19, 2024

OS Therapies Reports Second Quarter 2024 Financial Results

Accesswire August 15, 2024